Treatment of tinnitus with gabapentin: a pilot study.
Otol Neurotol. 2007 Jan; 28(1):11-5.ON

Abstract

OBJECTIVE

To evaluate the effectiveness of gabapentin (Neurontin) improve the disease-specific quality of life in patients with moderate tinnitus.

STUDY DESIGN

Randomized, double blind, placebo-controlled clinical trial.

SETTING

Single-center academic outpatient otolaryngology practice.

INTERVENTION

Gabapentin 1800 mg daily versus placebo.

MAIN OUTCOME MEASURES

The study design is a randomized, double blind placebo controlled single site trial conducted in an academic medical center. Inclusion criteria included patients between ages 18 and 70 with a complaint of nonpulsatile, subjective tinnitus, bilateral or unilateral, greater than 3 months in duration. The primary outcome measure is the Tinnitus Handicap Inventory; secondary measures include the Profile of Mood States (POMS) rating scale, subjective tinnitus severity. The null hypothesis addressed in this study is that the drug would not result in significant alleviation of the symptom of tinnitus.

RESULTS

Seventy-six patients completed the trial; of these 52 received the drug. No significant differences were found between the two groups after 5 weeks of treatment with gabapentin.

CONCLUSION

There is insufficient evidence to support the effectiveness of gabapentin in the treatment of tinnitus.

Links

Publisher Full Text
Aggregator Full Text

Authors+Show Affiliations

Witsell DL
Division of Otolaryngology, Head and Neck Surgery, Department of Surgery, Durham, North Carolina, USA. witse001@mc.duke.edu
Hannley MT
No affiliation info available
Stinnet S
No affiliation info available
Tucci DL
No affiliation info available

MeSH

AdolescentAdultAgedAged, 80 and overAminesAnalgesicsAuditory ThresholdCyclohexanecarboxylic AcidsDisability EvaluationDouble-Blind MethodDrug Administration ScheduleFemaleGabapentinHearing Loss, BilateralHearing Loss, UnilateralHumansMaleMiddle AgedMood DisordersPilot ProjectsQuality of LifeSeverity of Illness IndexSurveys and QuestionnairesTinnitusgamma-Aminobutyric Acid

Pub Type(s)

Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

17106432